The revision of GVP Module III (Pharmacovigilance Inspections) introduces important updates that Marketing Authorisation Holders (MAHs) should be aware of to strengthen inspection readiness and maintain compliance.
From enhanced risk-based inspection approaches to greater emphasis on oversight, documentation and inspection preparedness, these changes reinforce the need for robust pharmacovigilance systems and continuous compliance monitoring.
To help you navigate the key updates, our Pharmacovigilance experts have prepared a carousel highlighting the main changes and practical considerations for MAHs.
Swipe through to discover what the revised guidance means for your organisation and how to prepare for upcoming pharmacovigilance inspections: PV GVP Module III Revision 2
At Asphalion, we support pharmaceutical and biotech companies in building inspection-ready pharmacovigilance systems and navigating evolving regulatory requirements with confidence.
Contact us! [email protected]
